Repotrectinib in NTRK fusion–positive advanced solid tumors: a phase 1/2 trial

Journal:
Nature Medicine
Published:
Affiliations:
21
Authors:
24
Institutions Authors Share
Bristol-Myers Squibb, United States of America (USA)
6.000000
0.25
Institute Gustave-Roussy (IGR), France
1.000000
0.04
Mass General Brigham, United States of America (USA)
1.000000
0.04
Moores Cancer Center, United States of America (USA)
1.000000
0.04
National Cancer Center Hospital East, Japan
1.000000
0.04
Netherlands Cancer Institute (NKI), Netherlands
1.000000
0.04
Seoul National University Hospital (SNUH), South Korea
1.000000
0.04
Center for Integrated Oncology Aachen Bonn Köln Düsseldorf (CIO), Germany
1.000000
0.04
National Center for Tumor Diseases (NCT) Heidelberg, Germany
1.000000
0.04
The Royal Marsden NHS Foundation Trust, United Kingdom (UK)
1.000000
0.04
National Cancer Centre Singapore (NCCS), Singapore
1.000000
0.04
University of California, Irvine (UCI), United States of America (USA)
1.000000
0.04
Samsung Medical Center (SMC), South Korea
1.000000
0.04
Centre Georges-François Leclerc (CGFL), France
1.000000
0.04
START-Madrid-FJD, Spain
1.000000
0.04
Second People's Hospital of Hunan, China
1.000000
0.04
Peter MacCallum Cancer Centre (Peter Mac), Australia
1.000000
0.04
University of Washington (UW), United States of America (USA)
0.500000
0.02
Fred Hutchinson Cancer Center, United States of America (USA)
0.500000
0.02
Memorial Sloan Kettering Cancer Center (MSKCC), United States of America (USA)
0.500000
0.02
Weill Cornell Medicine, United States of America (USA)
0.500000
0.02